Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for BLS Pharmaceuticals's FCF Margin % or its related term are showing as below:
FRA:PR80'
s FCF Margin % Range Over the Past 10 Years
Min: -101.71 Med: -11.13 Max: 18.14
Current: 0.57
During the past 13 years, the highest FCF Margin % of BLS Pharmaceuticals was 18.14%. The lowest was -101.71%. And the median was -11.13%.
FRA:PR80's FCF Margin % is ranked better than 75.05% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs FRA:PR80: 0.57
BLS Pharmaceuticals FCF Margin % Related Terms
BLS Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (FRA:PR80) has a FCF Margin % of -7.25% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BLS Pharmaceuticals and its competitors. According to the industry distribution chart, BLS Pharmaceuticals ranks #237 out of 950 companies in the Biotechnology industry, placing it in the top 24.9%.
Is BLS Pharmaceuticals' FCF Margin % too high?
BLS Pharmaceuticals' current FCF Margin % is -7.25%. Based on the distribution chart, BLS Pharmaceuticals ranks #237 out of 950 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' FCF Margin % compare to ?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #237 out of 950 companies for FCF Margin %. This places BLS Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BLS Pharmaceuticals and its competitors. BLS Pharmaceuticals's current FCF Margin % is -7.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €0.58 — trading 41% above its estimated fair value. The current FCF Margin % is -7.25%. BLS Pharmaceuticals' overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current FCF Margin % is -7.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:PR80:
FCF Margin %: -7.25%
GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
37GF Score
Get the complete analysis for FRA:PR80
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PR80 has been successfully added to your 
